[go: up one dir, main page]

EP0105359A4 - AFFINITY PURIFICATION PROCESS USING MONOCLONAL ANTIBODIES. - Google Patents

AFFINITY PURIFICATION PROCESS USING MONOCLONAL ANTIBODIES.

Info

Publication number
EP0105359A4
EP0105359A4 EP19830901671 EP83901671A EP0105359A4 EP 0105359 A4 EP0105359 A4 EP 0105359A4 EP 19830901671 EP19830901671 EP 19830901671 EP 83901671 A EP83901671 A EP 83901671A EP 0105359 A4 EP0105359 A4 EP 0105359A4
Authority
EP
European Patent Office
Prior art keywords
environment
antigen
antibody
process according
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19830901671
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0105359A1 (en
Inventor
Richard M Bartholomew
Daniel E Beidler
Gary S David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of EP0105359A1 publication Critical patent/EP0105359A1/en
Publication of EP0105359A4 publication Critical patent/EP0105359A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Definitions

  • This invention relates to the purification of anti gens and antibodies by affinity chromatography. I another aspect it relates to monoclonal antibodies.
  • a pH of less than 3 or greater than 11 or concentrated chaotrope such as guanidine or urea solution can denature the antigen and the antibodies, diminishing if not destroying, the immunochemical and/or biologica properties of the antigen and shortening the useful lif of the immunoadsorbent.
  • immobilized antibodies o low affinity as an immunoadsorbent.
  • Use of these anti ⁇ bodies permits elution of the antigen from the body of immunoadsorbent using mild, non-denaturing conditions.
  • the requisite step of washing the column to elute impurities from the bound antigen also elutes some of the antigen, so much so that the efficiency of separation i greatly reduced.
  • low affinity antibodie cannot efficiently bind antigens which are present in th media at relatively low concentrations, i.e., less tha about 10 ng/ml.
  • hybridomas are -formed by the rando fusion of B-lymphocytes with myeloma cells in the presence of a fusion promoting agent.
  • Each hybridoma of the large population of hybridomas which can be produced by a fusion secretes a different monoclonal antibody.
  • the population of hybridomas is screened to select for furthe cloning those that secrete an antibody of the desired antigenic specificity in order to obtain useful quantities of antibody.
  • hybridomas which can be the product o multiple fusions, and identify those, which produce monoclonal antibody having a high affinity in a firs environment and a low affinity in a second environment an clone at least one of the hybridomas to obtain a suffi cient quantity of the antibody it produces to permi its use as a highly effective immunoadsorbent for affinit chromatography.
  • an antibody is considere to exhibit a high affinity when its affinity constant (Ka is about >_ 10 9 and to exhibit a low affinity when its K is about l ⁇ 8.
  • Figures 1 and 2 are graphs of data reflecting th effect of changes in pH on the desorption of radiolabele human growth hormone bound to four different monoclona antibodies immobilized on a solid phase.
  • purification of a antigen is accomplished by a process comprising th steps: a) selecting a monoclonal antibody having a high affinity for the antigen in a first environment and a low affinity for the antibody in a second environment, neither environment causing substantial, irreversible changes in the desired immunochemical properties of the antigen; b) immobilizing the antibody on a solid support; c) contacting the immobilized antibody with a sample containing impure antigen in the first environment to bind the antigen to the antibody; d) separating unbound impurities from the bound antigen; and e) eluting the antigen in a purified form from the immobilized antibody using, as an eluant, a medium which is the second environment.
  • antibodies useful in our invention can be obtained by screening the antibodies produced by a population of hybridomas obtained by the fusion, using known methods, of myeloma cells with B-lymphocytes.
  • the B—lymphocytes are typically spleen cells taken from a hype immunized animal to which the target antigen has previously been administered as an immunogen.
  • those hybridomas that produce monoclonal antibodies whose specificities are against the desired antigen have been identified, they can be further screened to identify those that produce antibodies whose affinities vary with changes in environment which are not damaging to the antigen or antibody.
  • antigens are usually stable in solution within the pH range of 4-10.5.
  • the population of monoclonal antibodies is screened to iden ⁇ tify those which have a high affinity for the antibody at one pH within the range, i.e., a Ka of about 10 9 and preferably > 10l0 and a low affinity at a second pH,
  • f Q i.e., a Ka of about 10 8 and preferably less than 10 within the same range.
  • This kind of screening can be don by immobilizing the antibody on a solid support and, afte permitting it to bind antigen, measuring the extent o desorption of the antigen that occurs at different p levels, a measurement which can be made, for instance, b employing radiolabeled antigen and counting the radiatio emitted by the solid phase and/or supernatant.
  • a simila screen can be carried out to identify antibodies tha respond to other kinds of environmental change. It is presently preferred to exploit monoclona antibodies whose capability to bind antigen is sensitiv to changes in pH.
  • the antibody is se lected to have a high affinity at one pH and a low af finity at a second pH which may be higher or lower tha the first pH ' .
  • the first pH will be at or near p 7 although it need not be.
  • tb select antibodies which respon to a different kind of change in environmental condition
  • a monoclonal antibody can be selected whic undergoes a change from high low affinity in the presenc of a chaotropic solution as the eluting medium.
  • Amon suitable chaotropes are KBr, KI, KSCN, guanidine, urea an MgCl2»
  • monoclonal antibodies can be selecte having a Ka > 10-** 1 in the absence of chaotrope but whic has a Ka of _ ⁇ 10*** in the presence of the particula chaotrope whose concentration is not detrimented to th antigen in question.
  • the selection for chaotrope sen sitivity can also be made in buffers at a specific pH.
  • antibodies can be selected which are sensitive to changes in pH in the presence of a constant concentration of a chaotrope.
  • Monoclonal antibodies whose affinity for an antigen is adequately lowered by changes other than pH or concen ⁇ tration of chaotrope can also be selected.
  • media sensitivity for which the antibodies can be screened to select those whose antigen binding ability i affected by a change in eluting medium can include borat sensitivity, methylmannoside sensitivity and sensitivit to non-ionic or ionic detergents and reagents whic affect specific amino acids such as tryptophan and tyro sine.
  • a selecte monoclonal antibody can be bound to any of the soli supports commonly used in affinity chromatography.
  • Thes include sepharose, polystyrene, glass, nylon, cellulose polymethyl methacrylate, silicagel, polyacrylamide an nitrocellulose.
  • Example 1 illustrates the application o the present invention to obtaining monoclonal antibodie whose binding affinity for an antigen varies from a hig affinity in a first environment to a low affinity in second environment, neither environment causing damage t the immunochemical properties of the antigen and thei usefulness as immunoadsorbents for affinity chromato graphy.
  • Example 1 illustrates the application o the present invention to obtaining monoclonal antibodie whose binding affinity for an antigen varies from a hig affinity in a first environment to a low affinity in second environment, neither environment causing damage t the immunochemical properties of the antigen and thei usefulness as immunoadsorbents for affinity chromato graphy.
  • HGH human growth hormone
  • NS-1 or SP-2/ lines poly ethylene glycol with mouse myeloma cells
  • the resulting hybridomas were cloned and screene to determine those secreting antibody specific for HGH b a radioimmunoassay employing 125 ⁇ -HGH and horse anti mouse IgG on sepharose beads.
  • the hybridomas producin anti-HGH were further screened to identify those producin antibodies having a Ka of at least about lO-**' at pH 7 These were further screened to identify those whose affin ities were sensitive to changes in pH over the range from to 10.5.
  • the supernatants eluted from antibodies A and C at p 4.0 and 10.5 were added to PBS buffer (10% in horse serum and adjusted to pH 7 and the samples pooled.
  • the poole samples were incubated with polystyrene balls coated wit antibodies A, B, C and D and two other monoclonal anti bodies against HGH. Each of these antibodies recogniz different areas of the HGH molecule.
  • the antibody was bound to sepharose bea using the CNBr technique at a concentration of 1 mg antibody per 1 ml of packed sepharose beads and used purify PAP from seminal fluid as follows. A 170 J ⁇ !
  • the PAP solution was passed through a column con taining 1.5 ml of the sepharose beads at the rate of ml/hour and the column washed with 7.5 mis of the startin buffer. Immunometric assay of the eluant (5 mis of sampl and 7.4 ml of wash liquid) demonstrated that 99.3% of th PAP had adsorbed to the column.
  • the PAP was eluted wit 0.1 M acetate buffer, pH 4 containing 0.15 M NaCl. Thre 1 ml fractions were collected and dlalyzed overnight vs 50 mM citrate, pH 6.0.
  • the PAP content of the pooled an dialyzed fractions was determined by immunoradiometri assay to be 54% of the total applied to the column Purity of the dialyzed material was determined by sodiu dodecyl sulfate and Ornstein-Davis PAGE. A single ban was observed in each case. Enzymatic activity measure ments were done and documented that the purified PA retained its enzymatic activity.
  • the retention of 46% of the PAP on the column i likely the result, at least in part, of non-specifi binding and the use of a large excess of antibody whic results in antigen "trail w from the column.
  • the forme can be reduced by pretreating the column with sample unde the conditions at which elution will be accomplishe followed by extensive washing to remove any materia which will elute. The latter can be reduced by lowerin the . concentration of bound antibody.
  • sepharos is not an ideal matrix for affinity chromatography becaus of the heterogeneity of pore size, resulting in diffusio and steric problems.
  • Hybridomas which produce monoclona antibodies against chlamydial antigen obtained by fusin spleen cells from hyperimmunized Balb/c mice with mous myeloma cells as described in Example 1, were screened fo
  • Table 3 The data in Table 3 were obtained by coating th antigen on microtiter plates and incubating it with solution of each of the antibodies in a buffer at th concentration of the detergent indicated in the tabl After incubation, the plate is washed and reacted wi polyclonal sheep anti-mouse antibodies labeled wi horse radish peroxidase (HRP). Incubations were for 1 h at room temperature. The plate is washed again a reacted with a solution of orthophenylenediamine (ODP), chromagen substrate for HRP. Absorbance in each well w measured at 490 nm and is reported in Table 3.
  • ODP orthophenylenediamine
  • Aqueous buffer is Autopow tissue culture media wit 8% horse serum, 2% fetal calf serum. All detergent used in the experiment were diluted in this buffer
  • Antibody No. 1 and Antibody 2 hav a relatively high affinity for Chlamydia in aqueous buffe that was not affected by any of the detergents except 2 NP-40.
  • Antibody 3 had a low affinity in 2% DOC, ye retained its high affinity in the other media.
  • Anti body 4 had a low affinity in 2% DOC and 2% NP-40 but high affinity in the other media.
  • the antigen coated microtite plates were first incubated with detergents in the concen trations shown in Table 3 for 1 hr. and then washed.
  • the antichlamydia antibodies were incubated i the wells followed, after washing, by an incubation with the HRP labeled anti-mouse antibodies. This incubation, after washing, was followed by an incubation with th enzyme substrate.
  • the optical densities measured in each well compared to wells which were pretreated with th aqueous buffer suggested that the antigen was not harmed by the detergents.
  • the monoclonal antibodies could be used for the affinity purification of the Chlamy ⁇ dia antigen by solubilizing the antigen in a detergen compatible with antibody binding and passing the prepara- tion over a column of immobilized antibody to bind the antigen. Subsequently, the antigen is released b eluting the column with another detergent composition i which the antibody does not bind to the antigen.
  • radiolabeled antibody used in an immunoradiometric assay which has degraded as a result of storage can be purified in this
  • the monoclonal antibody can also be recovered fro ascites fluid or culture medium by using the immobilize antigen as an immunoadsorbent.
  • the change in Ka with changes in pH is the likel effect of protonation of histidine residues or deprotona tion of lysine or possibly tyrosine or aginine residues i either the antibody, the antigen or both which alters th ability of the antigen and antibody to complex with eac other.
  • Specific residues affected may or may not li within the binding regions of the " molecules.
  • the antibodies produce by an animal's immune response to an antigen included antibodies that vary in their sensitivity to changes i environment, it is within the scope of our invention t fractionate polyclonal antisera to obtain a mixtur of antibodies which behave in a manner similar to th environmentally sensitive monoclonal antibodies of this invention.
  • This fractionation can be accomplished b contacting the immobilized antigen with an excess of th antisera in a first desired environmental condition followed by washing the immunoadsorbent to remove unbound material.
  • This step is followed by contacting the immno- adsorbent with a medium which is the second environment to elute antibodies which are not eluted under the first environmental condition.
  • the immobilized antigen is contacted with an excess of antisera at pH 7 and the immobilized antigen washed with a medium at pH 7 to remove antibodies which exhibit a low affinity at pH 7.
  • the immunoadsorbent is then eluted at pH 4 to remove anti ⁇ bodies which exhibit a low affinity at pH 4.
  • the eluant will contain the fraction of antibodies whose binding with the antigen is sensitive to changes in pH over the range pH 7 to pH 4. Similar fractionation can be done with urea and other inhibitors of antigen-antibody binding.
  • the resulting populations of antibodies may require further subfractionation to further remove those antibodies which elute due to an intrinsic low affinity rather than a Ka "switch". It is also within the scope of our invention to employ hybrid monoclonal antibodies having dual speci ⁇ ficities for affinity purification.
  • a process for ob ⁇ taining hybrid monoclonal* antibodies is described in the concurrently filed application of Martinis et al, "Anti- bodies Having Dual Specificities, Their Preparation And Uses Therefor", Serial No. —, (Lyon and Lyon Docket 162/98), the disclosure of which is incorporated by reference.
  • the hybrid monoclonal antibody has two specificities which may be for different antigens.
  • the hybrid antibody is selected to exhibit pH or other environmental sensitivity in the specificity for the antigen for which it is to be used as an immunoadsor ⁇ bent in an affinity chromatography.
  • the other specificity exhibited by the hybrid is selected to have a high affinity against a second antigen which is bound to a solid support.
  • the affinity of the hybrid for the second antigen must not be substantially lower in the environmental condition which will permit elution of the first, or target antigen.
  • the binding of second antigen to the antibody is sensitive to a different environmental condition than that which permits the target antigen to be eluted from the immuno ⁇ adsorbent.
  • the hybrid antibody may be selected so that the affinity for the target antigen is reduced by a lowering of pH and the affinity for the second antigen reduced by increasing the pH. This permits the hybrid monoclonal antibody to be desorbed readily from a solid support when it is desirable to do so because the support has become contaminated by impurities or oth reasons which impairs its usefulness.
  • the environmentally sensitive antibodies of ou invention can also be used to store antigens in a soli phase that are unstable in solution.
  • radio labeled antigen can be bound to the immobilized antibod for storage and desorbed as needed. Desorption can b preceded by washing the immunoadsorbent to remove an products of degration that arose during storage. Th reverse process is also possible, i.e., the antigen can b used to store unstable antibody in a solid phase.
  • radiolabeled antibody used in a radioassay can b stored as the antigen: antibody complex and desorbe as required.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19830901671 1982-04-12 1983-04-12 AFFINITY PURIFICATION PROCESS USING MONOCLONAL ANTIBODIES. Withdrawn EP0105359A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36778182A 1982-04-12 1982-04-12
US367781 1982-04-12

Publications (2)

Publication Number Publication Date
EP0105359A1 EP0105359A1 (en) 1984-04-18
EP0105359A4 true EP0105359A4 (en) 1984-08-20

Family

ID=23448565

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19830901671 Withdrawn EP0105359A4 (en) 1982-04-12 1983-04-12 AFFINITY PURIFICATION PROCESS USING MONOCLONAL ANTIBODIES.

Country Status (11)

Country Link
EP (1) EP0105359A4 (it)
AT (1) AT393386B (it)
AU (1) AU622099B2 (it)
CA (1) CA1209907A (it)
CH (1) CH672028A5 (it)
DK (1) DK192191D0 (it)
ES (3) ES521371A0 (it)
FI (1) FI88403C (it)
GB (1) GB2128630B (it)
IT (1) IT1219779B (it)
WO (1) WO1983003678A1 (it)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328918D0 (en) * 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
GB8331071D0 (en) * 1983-11-22 1983-12-29 Karayiannis P Assay for dna/rna
US4666865A (en) * 1984-01-13 1987-05-19 Centocor, Inc. Immunoassay for biologically active human interferon-gamma employing unique monoclonal antibodies
US4789631A (en) * 1984-02-17 1988-12-06 Synbiotics Corporation Immunoassay for anti-dirofilaria immitis antibody
GB8426468D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
AU5259786A (en) * 1985-01-30 1986-08-07 United States Of America, The Monoclonal antibodies against chlamydial genes specific lipopolysaccharide
US4859611A (en) * 1985-02-28 1989-08-22 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
US4818687A (en) * 1985-02-28 1989-04-04 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
IL75828A (en) * 1985-07-17 1991-06-10 Univ Ramot Immobilization by biologically active proteins
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5175255A (en) * 1987-03-23 1992-12-29 Amgen Inc. Methods for purification of platelet-derived growth factor
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
SE468653B (sv) * 1987-03-06 1993-02-22 Perstorp Biolytica Adsorbent foer isokratisk affinitetskromatografi
JPS6463599A (en) * 1987-05-01 1989-03-09 Xoma Corp Purification of immunoglobulin by selective anti-idiotype bond
ATE76974T1 (de) * 1987-07-14 1992-06-15 Univ Manchester Verfahren zur diagnose von infektionen, bei welchem lipopolyscaccharidantigene bestimmt werden.
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
CA2266341A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
NZ602884A (en) * 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982002818A1 (en) * 1981-02-26 1982-09-02 Gani Mohamed Mutwahar A process and apparatus for the recovery of immunoglobulins
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
EP0068763A2 (en) * 1981-07-01 1983-01-05 Board Of Regents, The University Of Texas System Recombinant monoclonal antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982002818A1 (en) * 1981-02-26 1982-09-02 Gani Mohamed Mutwahar A process and apparatus for the recovery of immunoglobulins
EP0068763A2 (en) * 1981-07-01 1983-01-05 Board Of Regents, The University Of Texas System Recombinant monoclonal antibodies
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Also Published As

Publication number Publication date
GB2128630B (en) 1986-08-28
FI88403B (fi) 1993-01-29
AU622099B2 (en) 1992-04-02
FI834530L (fi) 1983-12-09
IT1219779B (it) 1990-05-24
CA1209907A (en) 1986-08-19
GB2128630A (en) 1984-05-02
ES528001A0 (es) 1987-07-01
IT8320550A0 (it) 1983-04-12
AU7256987A (en) 1987-09-03
WO1983003678A1 (en) 1983-10-27
ES8506902A1 (es) 1985-08-01
ES8404858A1 (es) 1984-05-16
GB8332644D0 (en) 1984-01-11
FI88403C (fi) 1993-05-10
ES521371A0 (es) 1984-05-16
ATA901983A (de) 1991-03-15
DK192191A (da) 1991-11-26
DK192191D0 (da) 1991-11-26
CH672028A5 (it) 1989-10-13
FI834530A0 (fi) 1983-12-09
ES8706964A1 (es) 1987-07-01
ES528000A0 (es) 1985-08-01
EP0105359A1 (en) 1984-04-18
AT393386B (de) 1991-10-10

Similar Documents

Publication Publication Date Title
EP0105359A4 (en) AFFINITY PURIFICATION PROCESS USING MONOCLONAL ANTIBODIES.
Thompson et al. Purification of eukaryotic RNA polymerase II by immunoaffinity chromatography. Elution of active enzyme with protein stabilizing agents from a polyol-responsive monoclonal antibody.
Burgess et al. Advances in gentle immunoaffinity chromatography
US4833084A (en) Monoclonal antibody specific for DNA.RNA hybrids
Kabir Immunoglobulin purification by affinity chromatography using protein A mimetic ligands prepared by combinatorial chemical synthesis
Katz et al. Drug residue analysis using immunoaffinity chromatography
Hage et al. Immunoaffinity chromatography
EP0088974A2 (en) Homogeneous immunoassay with labelled monoclonal anti-analyte
US6531578B1 (en) Immunoassay method employing monoclonal antibody reactive to human iNOS
Abi-Ghanem et al. Immunoaffinity chromatography: a review
CN106146627A (zh) Fc特异结合蛋白、IgG亲和层析介质及其制备方法与应用
Schramm et al. Surface modification with protein A for uniform binding of monoclonal antibodies.
Thompson et al. Identification, production, and use of polyol-responsive monoclonal antibodies for immunoaffinity chromatography
Bonde et al. Selection of monoclonal antibodies for immunoaffinity chromatography: model studies with antibodies against soy bean trypsin inhibitor
Ohlson et al. High-performance liquid affinity chromatographic separation of mouse monoclonal antibodies with protein A silica
NO168969B (no) Fremgangsmaate for affinitetsrensing av et hybrid monoklonalt antistoff, fremgangsmaate for dets fremstilling og anvendelse av antistoffet
Evan A simple and rapid solid phase enzyme-linked immunoadsorbence assay for screening monoclonal antibodies to poorly soluble proteins
US20040063153A1 (en) Method for isolation of protein complexes using affinity binding
US4841024A (en) Purification of antibodies
Hadas et al. Enhanced activity of immobilized dimethylmaleic anhydride-protected poly-and monoclonal antibodies
Zeheb et al. An analytical method for the selective retrieval of iminobiotin-derivatized plasma membrane proteins
JP2825583B2 (ja) 細胞蛋白質の免疫検定法
Miller et al. Flow injection immunoassay using a protein A immunoreactor
JP2756162B2 (ja) 組換えタンパク質を対応の宿主細胞タンパク質から精製する方法
Jones et al. Monoclonal antibodies to leucine enkephalin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19831210

AK Designated contracting states

Designated state(s): BE DE FR NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BARTHOLOMEW, RICHARD M.

Inventor name: BEIDLER, DANIEL E.

Inventor name: DAVID, GARY S.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19931102

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BARTHOLOMEW, RICHARD M.

Inventor name: DAVID, GARY S.

Inventor name: BEIDLER, DANIEL E.